Hem › Levercancer (hepatocellulärt karcinom) › Pennsylvania › Philadelphia
Kliniska studier för Levercancer (hepatocellulärt karcinom) i Philadelphia, PA
16 studier för Levercancer (hepatocellulärt karcinom) söker deltagare vid platser i och runt Philadelphia (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekryterarFas 1
- Exelixis Clinical Site #98, Philadelphia
National Liver Cancer Screening Trial
RekryterarFas 4
- University of Pennsylvania, Philadelphia
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RekryterarFas 3
- Research Site, Philadelphia
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekryterarFas 1/2
- Children's Hospital of Philadelphia, Philadelphia
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekryterarFas 1/2
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
RekryterarFas 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi bort
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi bort
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RekryterarFas 2
- Thomas Jefferson University, Philadelphia
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Rekryterar
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Y-90 Treatment Response Using Transarterial Radioembolization
RekryterarFas 2
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
RekryterarFas 1/2
- University of Pennsylvania, Philadelphia
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
RekryterarFas 1/2
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RekryterarFas 2
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
SBRT With Atezo/Bev for HCC
RekryterarFas 1
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
RekryterarObservationsstudie
- Thomas Jefferson Hospital, Philadelphia
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RekryterarFas 4
- Albert Einstein Healthcare Network, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Philadelphia
Levercancer (hepatocellulärt karcinom)-studier i andra städer
- Houston, TX31 studier
- New York City, NY24 studier
- Dallas, TX19 studier
- Los Angeles, CA19 studier
- Boston, MA18 studier
- Cleveland, OH18 studier
- Chicago, IL16 studier
- Pittsburgh, PA15 studier
- San Francisco, CA14 studier
- Orange, CA14 studier
- Jacksonville, FL14 studier
- San Antonio, TX13 studier
Andra studier i Philadelphia
- Cancer (alla typer)59 studier
- Bröstcancer56 studier
- Icke-småcellig lungcancer51 studier
- Metastaserande cancer46 studier
- Prostatacancer44 studier
- Kolorektal cancer44 studier
- Äggstockscancer44 studier
- Lungcancer36 studier
- Akut myeloid leukemi34 studier
- Hjärtsvikt31 studier
- Endometriecancer28 studier
- Depression26 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.